Trial Profile
A phase 1, randomized, double-blind, placebo-controlled study to evaluate the pharmacokinetics, safety, and tolerability of CSL112 in healthy Japanese and Caucasian subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs CSL 112 (Primary)
- Indications Atherosclerosis; Myocardial infarction
- Focus Pharmacokinetics
- Sponsors CSL
- 04 Apr 2022 Data from 5 clinical trials (single and multiple ascending dose phase 1 studies in healthy volunteers, a phase 2a study in subjects with stable atherosclerotic disease, a phase 2b study in subjects post-AMI (AEGIS-I), and a phase 1 Japanese ethno-bridging study) assessing pharmacokinetics (PK) and pharmacodynamics (PD) of CSL112 across different populations, presented at the 71st Annual Scientific Session of the American College of Cardiology.
- 17 May 2021 Results presented at the 70th Annual Scientific Session of the American College of Cardiology.
- 22 Nov 2018 Status changed from recruiting to completed.